Radioisotopic Localization of 90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma

[1]  G. Denardo,et al.  Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies? , 2008, Cancer biotherapy & radiopharmaceuticals.

[2]  B. Bonavida,et al.  Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. , 2007, Cancer research.

[3]  J. Choi,et al.  Whole Body Positron Emission Tomography/Computed Tomography , 2006 .

[4]  R. Mertelsmann,et al.  The epitope recognized by rituximab. , 2006, Blood.

[5]  J. Vose,et al.  Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Vose,et al.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Vose,et al.  Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin’s lymphoma (NHL) , 2005 .

[8]  S. Skvortsov,et al.  Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. , 2005, Journal of radiation research.

[9]  T. Witzig,et al.  Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. , 2005, Cancer biotherapy & radiopharmaceuticals.

[10]  S. Horning,et al.  Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Denardo.  Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. , 2005, Seminars in oncology.

[12]  Hervé Watier,et al.  From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.

[13]  A. Bankier,et al.  Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. , 2004, Blood.

[14]  L. Gordon,et al.  Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. , 2004, Blood.

[15]  L. Gordon,et al.  Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Gressin,et al.  In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. , 2003, Blood.

[17]  M. Juweid.  Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  L. Gordon,et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Gordon,et al.  Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. , 2002, Blood.

[20]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[22]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Paradiso,et al.  Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[25]  W. Weng,et al.  Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. , 2001, Blood.

[26]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Sauerbruch,et al.  Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. , 2000, Cellular immunology.

[28]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[29]  Antonio J. Grillo-López,et al.  Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  L. Gordon,et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  O. Press.  Radiolabeled antibody therapy of B-cell lymphomas. , 1999, Seminars in oncology.

[32]  A. Zelenetz.  Radioimmunotherapy for lymphoma. , 1999, Current opinion in oncology.

[33]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Czerwinski,et al.  Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  T. Tedder,et al.  CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.

[36]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[37]  R. Frizzell,et al.  Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes , 1993, The Journal of cell biology.

[38]  J. Weinstein,et al.  Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.

[39]  G. Pinkus,et al.  Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. , 1984, Blood.